Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Primary Breast Cancer ER+ve × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 5717 Neoplasms 4761 Prostatic Neoplasms 2666 Colorectal Neoplasms 2387 Carcinoma, Non-Small-Cell Lung 2376 Lung Neoplasms 2010 Multiple Myeloma 1470 Lymphoma 1432 Neoplasm Metastasis 1385 Leukemia, Myeloid, Acute 1346 Melanoma 1326 Pancreatic Neoplasms 1314 Ovarian Neoplasms 1266 Leukemia 1240 Head and Neck Neoplasms 1138 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1119 Lymphoma, Non-Hodgkin 1081 Colonic Neoplasms 1030 Stomach Neoplasms 1007 Carcinoma, Hepatocellular 1007 Leukemia, Lymphocytic, Chronic, B-Cell 961 Brain Neoplasms 947 Rectal Neoplasms 877 Lymphoma, Follicular 857 Recurrence 856 Glioblastoma 822 Uterine Cervical Neoplasms 812 Carcinoma, Renal Cell 777 Lymphoma, Large B-Cell, Diffuse 746 Hodgkin Disease 690

Interventions

exemestane 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02676986 2024-07-05

ARB

Queen Mary University of London

Phase 2 Completed

Primary Breast Cancer ER+ve

Data powered by HemOnc (CC BY 4.0) Colophon ⚡